A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the change in estimated glomerular
filtration rate (eGFR) from baseline to Week 8 between placebo and GCS-100 treatment. The
secondary objective is to determine the safety and tolerability of GCS-100 administered for 8
weeks relative to placebo. In addition, the study will measure the effect of GCS-100 on
circulating galectin-3 and other markers of disease activity.